Next-Generation Sequencing (NGS) in Drug Discovery Market Size

The global next-generation sequencing (NGS) in drug discovery market was valued at approximately USD 1.62 billion in 2025 and is projected to reach nearly USD 4.68 billion by 2035, growing at a CAGR of 11.19%.

Next-Generation Sequencing (NGS) in Drug Discovery Market Growth Factors

The next-generation sequencing (NGS) in drug discovery market is experiencing rapid growth due to the increasing adoption of precision medicine, expanding genomics research, rising prevalence of cancer and rare genetic disorders, and growing investments in pharmaceutical and biotechnology R&D. Advances in sequencing technologies have significantly reduced sequencing costs while improving speed, accuracy, and throughput, making NGS accessible for large-scale research and clinical applications. The integration of artificial intelligence (AI), machine learning, cloud computing, and bioinformatics platforms is accelerating genomic data analysis and target identification. Government-funded genome initiatives, increasing collaborations between pharmaceutical companies and sequencing technology providers, and the growing demand for biomarker discovery and companion diagnostics are further supporting market expansion.

Additionally, the rise of personalized therapeutics, immunotherapy development, and multi-omics approaches continues to position NGS as one of the most influential technologies in modern drug discovery.

What is the Next-Generation Sequencing (NGS) in Drug Discovery Market?

The Next-Generation Sequencing (NGS) in Drug Discovery Market refers to the global ecosystem of technologies, instruments, reagents, software, and services that utilize high-throughput DNA and RNA sequencing to support every stage of pharmaceutical research and drug development.

Unlike traditional Sanger sequencing, NGS can sequence millions to billions of DNA fragments simultaneously, enabling researchers to analyze complete genomes, transcriptomes, epigenomes, and microbiomes in a single experiment. This capability dramatically accelerates disease understanding and the identification of therapeutic targets.

Drug developers use NGS for:

Gene mutation identification
Biomarker discovery
Target validation
Pharmacogenomics
Toxicogenomics
Clinical trial stratification
Companion diagnostics
Precision medicine development
Rare disease research
Oncology drug discovery

Today, nearly every major pharmaceutical company integrates NGS into its R&D pipeline to improve success rates while reducing drug development costs and timelines.

Get a Free Sample: https://www.cervicornconsulting.com/sample/2678

Why is Next-Generation Sequencing Important?

NGS has fundamentally changed pharmaceutical research because it enables scientists to understand diseases at the molecular level.

Its importance includes:

Accelerates Drug Discovery

Instead of investigating one gene at a time, researchers can study thousands of genes simultaneously, identifying disease-causing mutations much faster.

Enables Precision Medicine

NGS allows physicians and researchers to match therapies with a patient’s unique genetic profile, improving treatment outcomes while minimizing adverse effects.

Improves Clinical Trial Success

Patient stratification based on genomic biomarkers ensures that clinical trials enroll participants most likely to benefit from investigational therapies.

Supports Rare Disease Research

Thousands of rare diseases originate from genetic mutations that are difficult to identify without comprehensive sequencing technologies.

Advances Cancer Therapeutics

Tumor sequencing enables personalized oncology treatments by revealing actionable mutations and resistance mechanisms.

Reduces R&D Costs

Early identification of viable drug targets reduces expensive late-stage failures in pharmaceutical development.

Market Ecosystem

The NGS drug discovery market includes several interconnected segments:

Sequencing instruments
Library preparation kits
Reagents and consumables
Sequencing services
Bioinformatics software
Cloud-based genomic analytics
AI-powered genomic interpretation
Companion diagnostics
Clinical sequencing platforms

Consumables continue to generate recurring revenue because sequencing laboratories require new reagents and kits for every experiment.

Major Companies Driving Innovation

Company	Specialization	Key Focus Areas	Notable Features	2025 Revenue*	Estimated Market Position	Global Presence
Illumina, Inc.	High-throughput sequencing systems	Whole-genome sequencing, oncology, clinical genomics	NovaSeq X Series, extensive sequencing ecosystem	Approximately US$4.34 Billion	Global leader in NGS platforms	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Thermo Fisher Scientific Inc.	Life science instruments and sequencing	Clinical research, precision medicine, genetic analysis	Ion Torrent sequencing technology, integrated laboratory solutions	Approximately US$43+ Billion (company-wide) in 2025	Strong diversified life sciences player	Operations in over 50 countries
Agilent Technologies, Inc.	Genomics and analytical instruments	Target enrichment, sample preparation, genomics workflows	SureSelect technologies, bioinformatics integration	Approximately US$6.95 Billion	Major genomics workflow provider	More than 110 countries
F. Hoffmann-La Roche Ltd. (Roche)	Molecular diagnostics	Precision oncology, companion diagnostics, genomic medicine	Integrated diagnostics ecosystem and sequencing solutions	More than CHF 60 Billion (company-wide)	Global diagnostics leader	Over 100 countries
QIAGEN N.V.	Molecular diagnostics and sample technologies	Sample preparation, bioinformatics, companion diagnostics	QIAseq technologies, digital PCR, clinical genomics	Approximately US$2 Billion+ (company-wide)	Leading molecular biology solutions provider	More than 35 countries with worldwide distribution

*Company revenues represent overall corporate revenues rather than NGS-specific revenue because companies do not separately disclose sequencing-only sales.

Leading Trends and Their Impact

1. Artificial Intelligence Integration

AI algorithms now process enormous genomic datasets within minutes, identifying therapeutic targets that previously required months of analysis.

Impact:

Faster target identification
Better mutation prediction
Improved biomarker discovery
Reduced research costs

2. Multi-Omics Research

Drug discovery increasingly combines:

Genomics
Transcriptomics
Proteomics
Metabolomics
Epigenomics

This integrated approach provides a comprehensive understanding of disease biology.

3. Single-Cell Sequencing

Instead of analyzing millions of cells collectively, researchers examine individual cells.

Benefits include:

Understanding tumor heterogeneity
Identifying resistant cancer cells
Discovering new immune cell populations
Improving immunotherapy development

4. Long-Read Sequencing

Long-read technologies complement short-read sequencing by resolving complex genomic regions and structural variants.

Applications include:

Rare diseases
Neurological disorders
Cancer genomics
Population genetics

5. Cloud-Based Genomics

Cloud computing enables laboratories worldwide to process petabytes of genomic information securely and collaboratively.

Advantages include:

Lower infrastructure costs
Faster collaboration
Scalable storage
Global data sharing

6. Companion Diagnostics

NGS increasingly supports personalized drug selection by identifying patients most likely to respond to targeted therapies.

This trend is strengthening partnerships between pharmaceutical companies and diagnostics developers.

Successful Examples Around the World

Cancer Precision Medicine in the United States

Major cancer centers routinely perform comprehensive tumor sequencing before selecting treatment options.

NGS has enabled targeted therapies for:

Lung cancer
Breast cancer
Melanoma
Colorectal cancer
Leukemia

The result has been improved survival rates and more personalized treatment strategies.

Genomics England

The United Kingdom launched one of the world’s largest genomic medicine programs.

Whole-genome sequencing supports:

Rare disease diagnosis
Cancer treatment
Drug discovery research
Population health studies

This initiative has generated one of the world’s richest genomic datasets for pharmaceutical innovation.

All of Us Research Program (United States)

This national initiative aims to collect genomic, health, and lifestyle data from over one million participants.

Researchers use these datasets to identify:

Disease biomarkers
Drug targets
Population-specific genetic variations

The program accelerates precision medicine development.

China Precision Medicine Initiative

China has invested heavily in genomic sequencing infrastructure.

Major hospitals and research institutions utilize NGS for:

Oncology
Infectious diseases
Genetic disorders
AI-assisted genomic medicine

These investments continue to expand regional pharmaceutical innovation.

Japan’s Cancer Genome Medicine Program

Japan integrates NGS into clinical oncology to identify genomic alterations and guide precision therapies.

The program has strengthened collaboration among hospitals, pharmaceutical companies, and genomic research institutions.

European Cancer Research Networks

Several European Union-funded genomic collaborations are building cross-border sequencing databases that support:

Biomarker discovery
Rare disease research
Drug target validation
Clinical trial recruitment

Global Regional Analysis

North America

North America remains the largest market for NGS in drug discovery.

Growth Drivers

Advanced healthcare infrastructure
High R&D expenditure
Strong pharmaceutical industry
Extensive clinical genomics adoption
Leading sequencing technology companies

The United States dominates due to significant investments by biotechnology firms, academic research centers, and pharmaceutical companies.

Government Initiatives

Government support plays a major role through programs such as:

NIH genomic research funding
Precision medicine initiatives
Cancer Moonshot programs
FDA support for companion diagnostics
Large-scale genome sequencing projects

These initiatives encourage widespread adoption of sequencing technologies across research institutions.

Europe

Europe represents one of the fastest-growing genomic research markets.

Countries including:

Germany
United Kingdom
France
Netherlands
Switzerland

continue expanding precision medicine infrastructure.

Government Policies

European governments actively support genomic innovation through:

Horizon Europe research funding
National genome sequencing programs
Rare disease initiatives
Cross-border genomic collaborations
AI-driven healthcare strategies

Strong regulatory frameworks also encourage secure genomic data sharing while protecting patient privacy.

Asia-Pacific

Asia-Pacific is projected to experience the fastest market growth.

Major contributors include:

China
Japan
India
South Korea
Australia
Singapore

Growth Factors

Rapid biotechnology expansion
Government genomic investments
Rising healthcare spending
Growing pharmaceutical manufacturing
Increasing cancer prevalence

Government Initiatives

China

Precision Medicine Initiative
National Genome Programs
AI healthcare investments

Japan

Cancer Genome Medicine Project
National genomic databases

India

Genome India Project
Expansion of biotechnology parks
Digital healthcare initiatives

South Korea

National Bio Big Data Project
Government funding for genomic medicine

Australia

Australian Genomics Health Alliance
Precision oncology research funding

These initiatives continue attracting global pharmaceutical collaborations.

Latin America

Latin America is gradually adopting NGS technologies.

Countries including Brazil, Mexico, Argentina, and Chile are increasing investments in molecular diagnostics.

Government Support

Governments increasingly fund:

Cancer genomics research
Rare disease diagnosis
University genomics centers
Public-private biotechnology partnerships

Challenges remain regarding infrastructure and reimbursement, but adoption continues to rise.

Middle East & Africa

The Middle East and Africa represent emerging opportunities.

Countries such as:

Saudi Arabia
United Arab Emirates
South Africa

are investing in genomic medicine.

Government Policies

National healthcare transformation strategies emphasize:

Precision medicine
Biotechnology innovation
National genome projects
Digital healthcare ecosystems

Large government investments in biotechnology parks and genomic research centers are strengthening regional capabilities.

Future Opportunities in the Market

Several emerging opportunities are expected to drive continued expansion:

Pharmacogenomics

Sequencing enables personalized drug dosing based on individual genetic profiles.

Liquid Biopsy Development

NGS supports minimally invasive cancer detection using circulating tumor DNA.

Infectious Disease Research

Rapid pathogen sequencing improves vaccine development and antimicrobial resistance monitoring.

Rare Disease Therapeutics

Thousands of genetically driven rare diseases remain untreated, presenting enormous opportunities for sequencing-guided drug discovery.

AI-Powered Drug Discovery

Combining artificial intelligence with NGS data allows researchers to rapidly identify promising therapeutic candidates and predict treatment responses.

Expanding Clinical Applications

As sequencing costs continue to decline and reimbursement improves, NGS is expected to become a routine component of clinical decision-making, further accelerating demand for sequencing platforms, bioinformatics tools, and precision therapeutics.

The convergence of genomics, AI, cloud computing, and personalized medicine positions the next-generation sequencing (NGS) in drug discovery market as one of the most transformative segments within the global life sciences and pharmaceutical industry.